Article abstract-Objective: To describe a clinical syndrome of cerebellar ataxia associated with muscle coenzyme Q10 (CoQ10) deficiency. Background: Muscle CoQ10 deficiency has been reported only in a few patients with a mitochondrial encephalomyopathy characterized by 1) recurrent myoglobinuria; 2) brain involvement (seizures, ataxia, mental retardation), and 3) ragged-red fibers and lipid storage in the muscle biopsy. Methods: Having found decreased CoQ10 levels in muscle from a patient with unclassified familial cerebellar ataxia, the authors measured CoQ10 in muscle biopsies from other patients in whom cerebellar ataxia could not be attributed to known genetic causes. Results: The authors found muscle CoQ10 deficiency (26 to 35% of normal) in six patients with cerebellar ataxia, pyramidal signs, and seizures. All six patients responded to CoQ10 supplementation; strength increased, ataxia improved, and seizures became less frequent. Conclusions: Primary CoQ10 deficiency is a potentially important cause of familial ataxia and should be considered in the differential diagnosis of this condition because CoQ10 administration seems to improve the clinical picture.
In the past decade, mitochondrial encephalomyopathies due to mutations in mitochondrial DNA (mtDNA) have emerged as a major clinical group. Only recently has attention been directed to mutations in nuclear DNA that cause respiratory chain defects. However, in 1989, Ogasahara et al. 1 described a syndrome associated with coenzyme Q10 (CoQ10) deficiency in muscle, which was probably the first example of a mendelian defect in the respiratory chain. That syndrome, which was characterized by the triad of recurrent myoglobinuria, brain involvement, and ragged-red fibers (RRF)/lipid storage in muscle, was confirmed in a few additional cases, 2, 3 but the biochemical and molecular bases remain to be defined.
CoQ10, or ubiquinone, is a lipophilic component of the electron-transport chain, which transfers to complex III (ubiquinone-cytochrome c reductase) electrons derived from complex I (nicotinamide adenine dinucleotide, reduced form [NADH]-CoQ reductase), complex II (succinate dehydrogenase), and from the oxidation of fatty acids and branched-chain amino acids via flavinlinked dehydrogenases. 4 CoQ10 also plays a role as an antioxidant and as a membrane stabilizer. 5, 6 Decreased levels of muscle CoQ10 have been reported in patients with mitochondrial encephalomyopathies due to mtDNA mutations, but these were inconsistent and probably secondary findings. 7 In 1997, we studied a 37-year-old woman who had severe muscle CoQ10 deficiency and a clinical picture virtually identical to that of the patients described by Ogasahara et al. 3 To our surprise, one of 20 "disease control" muscle samples used in that study showed an extremely low level of CoQ10. The sample belonged to a 25-year-old man with hereditary ataxia, without RRF or lipid storage. This serendipitous finding prompted us to measure CoQ10 in muscle biopsies from other patients with unexplained ataxia. Our interest in this association was bolstered by the report of a child with ataxia, cerebellar atrophy, and generalized seizures, whose muscle biopsy showed complex III deficiency and severe CoQ10 deficiency. 8 Patients and methods. Case reports. Patient 1. An 11-year-old boy had a normal newborn period and early motor development, but at 1 year of age he was noted to be clumsy and to fall frequently. At age 3, he developed ataxia and myoclonus. A cranial MRI scan showed the Dandy-Walker variant with enlargement of the fourth ventricle, and a ventriculoperitoneal shunt was placed. However, his condition worsened steadily and at age 7 years he developed generalized tonic-clonic seizures, which were partially controlled with valproic acid. His parents were normal and nonconsanguineous, and his 9-year-old sister appeared healthy; his mother and sister had normal neurologic examinations. General physical examination was normal. Neurologically, he was alert, with normal ocular fundi. Eye movements had impaired smooth visual pursuit and end-gaze horizontal nystagmus. Limb tone was decreased and tendon reflexes were absent. There were synchronous and asynchronous myoclonic jerks. Also, there was decomposition of rapid alternating movements and finger-nose testing was performed poorly. Balance was unsteady and gait was ataxic. Plantar responses were flexor. The clinical picture was considered consistent with Ramsay-Hunt syndrome or early-onset Friedreich ataxia. Abnormal laboratory tests included increased blood ammonia (64 mol/L; normal, 11 to 32 mol/L) and arterial lactate (2.0 mmol/L; normal, 0.5 to 1.6 mmol/L). EEG showed generalized slowing and lack of organization of activity with multifocal sharp wave-and-spike and slow wave activity. A CT scan of the head showed atrophy of the cerebellum, a finding confirmed by MRI at age 10 years (figure, a). Muscle biopsy at age 8 years showed excessive variation of fiber sizes and scattered cytochrome c oxidase (COX)-deficient fibers.
By age 8 years, he was confined to a wheelchair and unable to feed himself. Treatment with CoQ10 (600 mg/d) caused remarkable improvement within 3 months, which was clearly noticeable to his mother and his teachers and was recorded by his physician. He was able to walk independently, though he was unsteady and tremulous. He spoke much more clearly. He could reach for objects with difficulty but with good targeting. However, at age 10 years his seizure disorder worsened considerably, with the appearance of focal motor in addition to generalized tonicclonic seizures, which were difficult to control pharmacologically. In addition, his mother admitted to poor compliance with the CoQ10 administration because of economic problems. Concomitant with these events, there has been a marked worsening of his cerebellar dysfunction.
Patient 2. This 17-year-old girl was born at term after an uneventful pregnancy and labor, but showed global developmental delay since the first few months of life and did not walk until 3 years of age. Generalized seizures started at age 2 years, requiring phenytoin administration. She developed no expressive or receptive language function and was severely mentally impaired. Progressive ataxia became evident at age 13 years. She was an only child and family history was noncontributory. Neurologic examination showed mental retardation with both receptive and expressive language problems, spastic quadriparesis, severe trunk ataxia (she could not walk even with assistance), generalized hyperreflexia, and dysphagia.
Laboratory tests were normal, including serum ammonia, lactate, amino acids, lysosomal enzymes, and urinary organic acids. Molecular analyses for Friedreich ataxia and other forms of hereditary SCA were not performed because generalized seizures and mental retardation from infancy are not compatible with any of these conditions. Karyotype was normal. Brain MRI showed agenesis of the corpus callosum and atrophy of the cerebellar vermis (see the figure, c). Muscle biopsy showed nonspecific myopathic changes. After 1 month of CoQ10 administration (300 mg/ d), her ataxia improved and she could walk with assistance. She is currently taking CoQ10 600 mg/d; her trunk ataxia persists and she needs assistance in walking.
Patient 3. A 25-year-old man had normal early developmental milestones, but at 2 years of age he was considered clumsy and hyperactive and slurred speech was noted at age 3 years. By age 4 years, he developed overt ataxia and was confined to a wheelchair at age 6 years. He was cognitively impaired and required special education. A muscle biopsy at age 6 years was nondiagnostic. By age 20 years, he had generalized weakness and wasting, required a motorized wheelchair, and needed assistance for dressing and personal care. Two younger twin siblings, a man and a woman (Patients 4 and 5), were similarly affected, and two other siblings were normal. His parents were healthy and there was no known consanguinity. Neurologic examination was similar in all three siblings, who were wheelchair bound, with titubation of the head and severe limb ataxia with the slightest purposeful movement. All three had distal wasting and pes cavus. Strength was diffusely reduced in both arms and legs. Tendon reflexes were absent and sensation was normal. All three patients had alternating esotropia. Scoliosis was also present in all three, and was more severe in Patient 5 (see below). Normal laboratory tests included urine organic acids, plasma amino acids, serum lactate and pyruvate, CSF lactate and pyruvate, and blood levels of vitamin E. Molecular analyses excluded Friedrich's ataxia and SCA. An MRI scan of the brain showed cerebellar atrophy in all three patients (see the figure, b).
At age 21 years, CoQ10 supplementation was started, and the dosage was increased from 300 to 3,000 mg/d during the next 3 years. The patient's strength improved enough to allow him to return to a manual wheelchair and to ambulate with a rolling walker. There was improvement in the heel-to-shin and finger-to-nose tests. By age 23 years, he could climb up steps holding onto a rail and with minimal assistance, and had become independent in his daily activities except for shaving. In addition, he had gained about 23 kg and the severity of his scoliosis had decreased from 19°to less than 10°.
Patient 4. A 24-year-old woman, a sister of Patient 3, also had normal development until age 4 years, when she became clumsy and developed fainting spells characterized by screaming, holding her abdomen, and collapsing for less than a minute, followed by lethargy and sleep. These spells occurred two or three times, then disappeared until age 7 years, when she began having grand mal seizures. The ataxia became progressively worse and she became nonambulatory at age 8 years. She attended a regular school and graduated from high school at a normal age. During adolescence, she developed increasing scoliosis, reaching 64°. Family history, neurologic examination, and laboratory results are described above (see Patient 3) .
At age 20 years, CoQ10 supplementation was started, rapidly reaching dosages of 3,000 mg/d. Although her ataxia did not improve significantly, she became seizurefree and her strength increased enough to allow her to walk about 20 m with a rolling walker and on a treadmill for 10 minutes. She regained independence in the activities of her daily living and does floral design work. Radiologically, the curvature of her scoliosis decreased by 10°.
Patient 5. A 24-year-old man, twin brother of Patient 4, was normal until 4 years of age, when excessive drooling, poor coordination, and hyperactivity were noted. He had frequent upper respiratory tract and middle ear infections. At age 5 years, he developed choreic movements, became increasingly ataxic, and lost ambulation. He developed severe scoliosis (100°) for which he underwent surgery at age 18 years. A muscle specimen was obtained during surgery, in which we documented CoQ10 deficiency. Family history, neurologic examination, and laboratory results are described above (see Patient 3) .
At age 20 years, he began treatment with CoQ10 (300 mg/d, gradually increased to 3,000 mg/d) and his strength improved to the point that he could walk about 15 m with a rolling walker and climb up steps using a rail, with minimal assistance. Ataxia has not changed.
Patient 6. A 20-year-old woman had normal development through childhood and adolescence, except for a mild stammer. She was an excellent student and at age 9 years won a sports prize. At age 16 years, she first noticed difficulties going down staircases and had to hold to handrails for fear of falling. She also developed problems walking because her legs "crossed" and she tended to deviate to the right. She was an only child; her parents were healthy and not consanguineous. Neurologic examination at age 17 years showed an alert and articulate young woman with a stutter and a mild cerebellar scanning speech pattern. Vision and fundi were normal. Ocular motility was full, but extraocular movements showed coarse end-lateral gaze nystagmus with a rotatory component, but no oscillopsia. Muscle tone was normal. Distal limb muscles were less well developed than proximal muscles and intrinsic hand muscles were mildly weak. Sensation, including proprioception, was normal. Finger-nose-finger testing showed mild dysmetria and heel-to-shin was grossly ataxic. Her gait was mildly scissoring and clumsy and she was unable to tandem. Romberg sign was absent. Tendon reflexes were brisk and there were a few beats of ankle clonus. Hoffmann sign was present but plantar responses were flexor. Routine laboratory tests, including complete blood count, blood chemistries, and thyroid function, were normal. The profile of urinary organic acid was normal, excluding methylmalonic aciduria (courtesy of Dr. Piero Rinaldo, Mayo Clinic, Rochester, MN). Chest radiography and electrocardiogram results were normal. Motor and sensory nerve conductions were normal and electromyography showed a mildly reduced mean motor unit potential duration, indicative of a myopathic process. A biopsy of
At age 17 years, she began taking CoQ10 (200 mg three times a day with meals) and both she and her mother think that she "improved a lot"; her balance was better and her speech was more fluent. She reported that her legs rarely crossed while walking. She walked 10 to 15 blocks but could not carry heavy bags while walking because of imbalance. She commuted by subway to a job at a store, where she answered telephone calls, worked with a computer, and occasionally functioned as a salesperson. When examined again at age 20 years, her stutter had improved and her finger-nose-finger testing was less dysmetric, though her heel-to-shin remained grossly ataxic. Gait was narrow based with stiff legs, without scissoring. Tendon reflexes remained brisk, with 1 to 2 beats of ankle clonus. Hoffmann and Babinski signs were absent.
Biochemical assays. Spectrophotometric assays for NADH dehydrogenase (complex I), rotenone-sensitive NADH-cytochrome c reductase (complex I ϩ III), succinate-cytochrome c reductase (complex II ϩ III), succinate dehydrogenase (complex II), cytochrome c oxidase (complex IV), and citrate synthase were performed as described. 9 Respiratory chain enzyme activities were referred to the activity of citrate synthase.
CoQ10 concentration in muscle extracts and in cultured skin fibroblasts was measured using a modification of the method described by Lang et al. 10 CoQ10 extraction was performed at 4°C with ethanol-n-hexane. After complete evaporation under a stream of nitrogen, the residue was dissolved in 1.0 mL of ethanol/methanol mixture (65:35 volume to volume ratio) and the concentration of CoQ10 was determined by reverse phase high-performance liquid chromatography (HPLC) on a C18 column and ultraviolet detection at 275 nm, using CoQ9 as an internal standard.
Results.
The clinical features of the six patients are summarized in table 1. All patients had cerebellar ataxia, which started in childhood in five of them, but was only noted at age 16 years in Patient 6, who had been a good athlete as a child. Likewise, the severity of the ataxia distinguished the first five patients (three of whom were siblings) from Patient 6. Patients 1 to 5 were confined to a wheelchair by age 8 years, whereas Patient 6 is still ambulatory at age 20 years. In addition, symptoms and signs other than ataxia were more common in Patients 1 through 5 than in Patient 6. Thus, generalized seizures were seen in Patients 1, 2, and 4; Patients 2, 3, and 5 had cognitive impairment; myoclonus suggested the diagnosis of Ramsey-Hunt syndrome in Patient 1; and weakness was prominent in the three siblings (Patients 3 through 5), resulting in severe scoliosis. Conversely, Patient 6 had pyramidal signs and mild distal weakness and wasting.
Family history suggested autosomal recessive transmission in Patients 3 through 5, who were similarly affected, but whose parents and two siblings were in good health; it was noncontributory in the other three patients, but also consistent with autosomal recessive inheritance.
Laboratory examination results were generally negative; in particular, blood lactate was mildly increased only in Patient 1, but it was not measured in the CSF. Molecular tests excluded Friedrich's ataxia and most forms of SCA in five patients. Molecular tests seemed unwarranted in Patient 2 because infantile seizures and mental retardation are not compatible with any of the SCA types. Electrodiagnostic tests showed abnormal EEG in the patients with seizures, whereas electromyography showed nonspecific myopathic features in all patients. Muscle biopsy was also nonspecifically abnormal in all patients, without evidence of mitochondrial proliferation or lipid storage. There was no clinical or laboratory evidence of cardiac involvement. The only laboratory test that was markedly abnormal in all patients was the MRI of the brain, which showed severe cerebellar atrophy (see the figure) .
In agreement with muscle morphology, biochemical studies showed no evidence of mitochondrial proliferation because the activity of citrate synthase, a matrix enzyme and a good marker of mitochondrial abundance, was normal in all patients. Respiratory chain enzymes activities suggested complex III deficiency in Patients 1 and 6, complex I deficiency in Patient 2, and a combined deficiency of complexes I, III, and IV in Patient 3 (table 2) .
CoQ10 concentration was decreased in muscle from all patients, with residual amounts varying from 26% of controls in Patient 2 to 35% in Patient 1 (table 3) . Control muscle was obtained by diagnostic biopsy (quadriceps muscle) from individuals who were ultimately deemed to be free of muscle disease. Although residual CoQ10 concentration was substantial, the decrease was significant. The content of CoQ10 in cultured fibroblasts was less markedly decreased, with residual concentrations ranging between 54 and 71% of controls: however, the differences between patients and controls were also significant (see table 3 ).
CoQ10 administration improved cerebellar function in five patients, as reflected by the decreases in the International Cooperative Ataxia Rate Scale scores (table 4).
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Discussion. Although the clinical presentation varied considerably in the six patients, they all shared three fundamental features: cerebellar ataxia, cerebellar atrophy, and muscle CoQ10 deficiency responsive to CoQ10 supplementation.
The serendipitous finding of low CoQ10 content in the muscle biopsy of Patient 3 and the dramatic response of this patient and his affected siblings (Patients 4 and 5) to CoQ10 supplementation prompted us to measure CoQ10 in muscle biopsies from three other patients with undiagnosed, apparently autosomal recessive ataxia. All three had similar decreases of CoQ10 concentration in muscle and all three responded clearly to replacement therapy, suggesting the possibility that ataxia and cerebellar atrophy may be the consequence of primary CoQ10 deficiency.
Primary muscle CoQ10 deficiency was first described in 1989 in two sisters with recurrent episodes of myoglobinuria and muscle biopsies characterized by RRF and lipid storage.
1 Three other patients with the same syndrome were described later. 2, 3 Although the clinical picture in these four patients was dominated by NADH ϭ nicotinamide adenine dinucleotide, reduced form; ND ϭ not determined.
myopathy, it is noteworthy that all four also had CNS involvement. The two sisters were reported to have learning disability and abnormal EEG tracings, though only one developed generalized seizures. 1 At age 12 years, the older sister developed a slowly progressive cerebellar syndrome with dysarthria, limb ataxia, and tremor of the head and trunk.
1 Two brothers were reported to have seizures, 2 and one woman had delayed motor development, bilateral ptosis and restricted upgaze, migraine, and complex partial seizures with occasional secondary generalization. 3 In this woman, however, cerebellar function appeared normal and CT scan of the brain revealed cerebral rather than cerebellar atrophy. 3 A patient reported from a previous study 8 seems to fall between the six patients described here and those with mitochondrial myopathy and myoglobinuria. This 4-year-old boy had delayed motor development, a mitochondrial myopathy without myo-globinuria, bilateral ptosis, generalized seizures, pigmentary degeneration of the retina, cerebellar ataxia with dysarthria and tremor, and severe cerebellar atrophy. Thus, primary muscle CoQ10 deficiency seems to be associated with a spectrum of clinical presentations always involving both muscle and brain but ranging from a predominantly myopathic to a predominantly encephalopathic syndrome.
Our patients illustrate the encephalopathic presentation of CoQ10 deficiency, and the apparent selective vulnerability of the cerebellum, with cerebellar atrophy and ataxia. The reasons for the different involvement of muscle and brain are not clear but may be related to different degrees of CoQ10 deficiency in the two tissues. Residual levels of CoQ10 in muscle mitochondria or in muscle homogenates varied between 4 and 16% in four patients with mitochondrial myopathy 1, 3, 8 but averaged 25% in our patients with ataxia. Accordingly, the activities of complex I ϩ III and II ϩ III, which depend on CoQ10, were more consistently and markedly decreased in muscle from patients with myopathy than in our patients with encephalopathy. Another interesting difference between the two groups of patients is the concentration of CoQ10 in fibroblasts, which was normal in three patients with myopathy 1, 3, 8 but decreased in all six patients with predominant brain involvement.
CoQ10 is a component of the electron transport chain located in the inner mitochondrial membrane, where it transfers electrons from complex I (NADHCoQ reductase) and complex II (succinate dehydrogenase) to complex III (cytochrome bc 1 complex). CoQ10 might have other oxidoreductase functions in the Golgi apparatus and in the plasma membrane related to vesicle migration, cell growth, and signal transmission. 12 In addition, there is evidence that CoQ10 may function as an antioxidant and as a membrane stabilizer. CoQ10, like all ubiquinones, is composed of a benzoquinone ring and an isoprenyl side chain, which, in humans and most other animals, contains 10 isoprenyl groups. Intracellular synthesis is the major source of CoQ10, though some of it is acquired through the diet. CoQ10 biosynthesis begins with the formation of a polyisoprenyl chain, which is then transferred to the aromatic ring of parahydroxybenzoate (PHB). In animals, PHB derives from tyrosine or phenylalanine and is then converted to 4-hydroxybenzoate. The first committed step in CoQ10 biosynthesis is the transfer of splanesyl-pyrophosphate to 4-hydroxybenzoate. 13 In eukaryotes, the aromatic ring then undergoes hydroxylation, methylation, and decarboxylation to form CoQ10. The complexity of CoQ deficiency is illustrated by the fact that in fission yeast there have been identified different complementation groups and different phenotypes associated with CoQ deficiency. 14, 15 In humans, the only known inborn error in the biosynthesis of isoprenoid compounds (as well as cholesterol) is mevalonic aciduria, an autosomal recessive disease due to mevalonate kinase deficiency. 16 It is noteworthy that children with the less severe form of mevalonic aciduria present with psychomotor retardation, myopathy, cerebellar ataxia, and selective cerebellar atrophy by neuroimaging. The decreased levels of CoQ10 found in the plasma of these children (CoQ10 was not measured in muscle or other tissues) provides further evidence that the cerebellum may be especially vulnerable to CoQ10 deficiency. The complexity of CoQ10 biosynthesis suggests that different biosynthetic enzyme defects may cause different clinical syndromes, including perhaps the clinical variants characterized by myopathy or encephalopathy. A report 17 described yet another clinical variant, with severe encephalomyopathy and renal disease in three siblings, one of whom died at age 8 years of renal failure. Onset was in infancy, and two siblings had ataxia; however, a CT scan of the brain showed cerebral and cerebellar hypodensity rather than cerebellar atrophy. The decreased level of CoQ10 in cultured skin fibroblasts from our patients will allow us to study CoQ10 biosynthesis in vitro in search of the defective enzymatic step (or steps). Similar studies in the siblings with encephalomyopathy and nephropathy suggested a defect of trans-prenyltransferase, but no mutations were identified in this enzyme's complementary DNA. 17 Patients with the predominantly myopathic variant were treated with relatively low doses of CoQ10 (150 mg/d) and were reported to improve "subjectively," 3 or in terms of strength but not ataxia. 8 Details about the response to therapy were not provided, except for the two brothers reported by Servidei et al., 2 in whom "symptoms resolved completely" and repeat biopsies showed normalization of CoQ10 concentration and respiratory chain enzyme activities, disappearance of lipid storage, but increased numbers of RRF. Two of the three siblings with encephalomyopathy and nephropathy responded dramatically to oral ubidecarenone (90 mg/d). 17 We treated our patients with high doses of CoQ10, ranging from 300 to 3,000 mg/d, with dramatic improvement in strength and well-being, better control of seizures, and some improvement of cerebellar function, as detailed above in the case reports and documented by decreased ataxia scores (see table 4 ). The improvement was documented through repeat videotapes in Patient 1 and in Patients 3 through 6 was clearly recorded by physicians in follow-up consultations, and was noted by both patients and relatives, who were reluctant or unwilling to discontinue or reduce CoQ10 supplementation. In Patient 1, improvement was followed by a relapse to baseline values that, however, seemed to coincide with worsening seizure disorder and poor compliance.
Our findings, and especially the response to replacement therapy, suggest the importance of considering CoQ10 deficiency in the differential diagnosis of hereditary SCAs. This is a large group of disorders with different modes of inheritance in which increasing numbers of molecular defects are being described. 18 In our patients, the autosomal dominant forms of SCA (SCA-1 to SCA-5) could be excluded based on family history and molecular studies. Likewise, Friedreich's ataxia was excluded both on clinical and on molecular grounds. Vitamin E levels were normal in all patients, and mtDNA defects, such as myoclonus epilepsy with ragged-red fibers, MERRF, were excluded by the lack of maternal inheritance, virtually normal muscle morphology, and normal sequence of the mtDNA transfer RNA Lys .
Reactive oxygen species toxicity is thought to be a common mechanism leading to at least three forms of hereditary ataxia: Friedreich's ataxia, abetalipoproteinemia, and ataxia with isolated vitamin E deficiency. [19] [20] [21] CoQ10 deficiency could be another inherited ataxia due to oxidative damage. The specific biochemical steps, genes, and molecular defects involved in different patients remain to be identified, but measurement of CoQ10 concentration in muscle establishes the diagnosis and is an indication for aggressive and early replacement therapy.
